Departments of Pathology.
Genitourinary Medical Oncology.
Am J Surg Pathol. 2022 Jan 1;46(1):11-17. doi: 10.1097/PAS.0000000000001789.
The development of somatic-type malignancies (SMs) in testicular germ cell tumors (GCTs) is a rare but well-recognized phenomenon. We studied the pathologic features of 63 GCTs with SMs in the testis (n=22) or metastases (n=41) and correlated these features with clinical outcomes. The patients with SMs in the testis (median age, 26 y) were younger than those with metastatic SMs (median age, 38.5 y). The SMs consisted of carcinomas (n=21), sarcomas (n=21), primitive neuroectodermal tumors (n=15), nephroblastomas (n=3), and mixed tumors (n=3). Sarcoma was the most common SM in the testis (n=11), and most sarcomas were rhabdomyosarcomas (n=9). Carcinoma was the most common SM in metastases (n=20), and most carcinomas were adenocarcinomas (n=12). In metastases, carcinomatous SMs developed after a longer interval from the initial orchiectomy (median times, 213 mo) than sarcomatous SMs (median times, 68 mo). Patients with metastatic SMs had significantly poorer overall survival than those with SMs in the testis (5-y survival rate, 35% vs. 87%; P=0.011). Furthermore, patients with carcinomatous SMs had a significantly worse prognosis than those with sarcomatous or primitive neuroectodermal tumor SMs (5-y survival rates, 17%, 77%, and 73%, respectively; P=0.002), when the whole cohort, including testicular and metastatic SMs, were analyzed. Our results demonstrate that SMs in metastatic GCTs are associated with a significantly worse prognosis than those in the testis. Furthermore, the histologic subtype of SM has a significant effect on the clinical outcome, with the carcinomatous SM carrying the highest risk for mortality.
在睾丸生殖细胞瘤(GCT)中发生的体瘤型恶性肿瘤(SMs)是一种罕见但已被充分认识的现象。我们研究了 63 例 GCT 中睾丸(n=22)或转移部位(n=41)中具有 SM 的肿瘤的病理特征,并将这些特征与临床结局相关联。睾丸中具有 SM 的患者(中位年龄,26 岁)比转移性 SM 患者(中位年龄,38.5 岁)年轻。SM 包括癌(n=21)、肉瘤(n=21)、原始神经外胚层肿瘤(n=15)、肾母细胞瘤(n=3)和混合瘤(n=3)。肉瘤是睾丸中最常见的 SM(n=11),且大多数肉瘤为横纹肌肉瘤(n=9)。癌是转移部位中最常见的 SM(n=20),且大多数癌为腺癌(n=12)。在转移部位中,癌性 SM 比肉瘤性 SM 从初始睾丸切除术(中位时间,213 个月)后更长的时间发展(中位时间,68 个月)。具有转移性 SM 的患者的总体生存率明显低于睾丸中具有 SM 的患者(5 年生存率,35%比 87%;P=0.011)。此外,在整个包括睾丸和转移性 SM 的队列中,当分析时,具有癌性 SM 的患者比具有肉瘤性或原始神经外胚层肿瘤性 SM 的患者预后明显更差(5 年生存率,17%、77%和 73%;P=0.002)。我们的结果表明,转移性 GCT 中的 SM 与预后明显较差相关,而在睾丸中则不然。此外,SM 的组织学亚型对临床结局有显著影响,癌性 SM 的死亡率最高。